CenterBook Partners LP Has $9.96 Million Stock Holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

CenterBook Partners LP trimmed its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 43.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 109,417 shares of the company's stock after selling 84,701 shares during the quarter. BioNTech accounts for 0.6% of CenterBook Partners LP's portfolio, making the stock its 29th largest position. CenterBook Partners LP's holdings in BioNTech were worth $9,964,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in BNTX. Charles Schwab Investment Management Inc. raised its holdings in shares of BioNTech by 30.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 243,468 shares of the company's stock worth $22,170,000 after acquiring an additional 56,113 shares in the last quarter. Costello Asset Management INC bought a new position in BioNTech during the first quarter valued at approximately $91,000. Baader Bank Aktiengesellschaft increased its stake in shares of BioNTech by 1.7% during the 1st quarter. Baader Bank Aktiengesellschaft now owns 142,822 shares of the company's stock worth $12,937,000 after purchasing an additional 2,422 shares during the last quarter. Harvest Fund Management Co. Ltd acquired a new position in BioNTech during the first quarter worth $227,000. Finally, Banque Cantonale Vaudoise bought a new position in BioNTech during the first quarter valued at about $36,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on BNTX. Citigroup reissued a "buy" rating and issued a $140.00 price objective (down from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. HC Wainwright reissued a "buy" rating and issued a $138.00 price target on shares of BioNTech in a research report on Wednesday, June 25th. Truist Financial reaffirmed a "buy" rating and set a $155.00 price objective (up from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Leerink Partners set a $112.00 price target on BioNTech in a research report on Monday, June 2nd. Finally, Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $136.58.

BioNTech Price Performance

Shares of BNTX stock traded down $0.99 during mid-day trading on Thursday, reaching $111.50. The company's stock had a trading volume of 277,177 shares, compared to its average volume of 940,371. The firm's 50-day moving average is $104.47 and its two-hundred day moving average is $106.80. The company has a market cap of $26.80 billion, a P/E ratio of -32.81 and a beta of 1.29. BioNTech SE Sponsored ADR has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.